• SPECIALTY
  • PROVIDER INFO
  • EDUCATION
  • AFFILIATIONS
  • RESEARCH & PUBLICATIONS
  • ACHIEVEMENTS
  • PATIENT RATINGS & COMMENTS

Office locations

Los Angeles
Los Angeles
Samuel Oschin Cancer Center
3104232217
127 S. San Vicente Blvd. 7th Floor
Los Angeles
CA
90048
Cedars-Sinai Medical Center
3104232217
8700 Beverly Blvd Ste AC1042C
Los Angeles
CA
90048

Specialty

  • IM/Hematology/Oncology

    Provider Info

    GENDER

    Male

    LANGUAGES

    Spanish, English

    EXPERIENCE

    18 years

    Education

    • University of Southern California
      Fellowship - Completed 2010
    • Los Angeles County + USC Medical Center
      Residency - Completed 2007
    • Los Angeles County + USC Medical Center
      Internship - Completed 2006
    • Tulane University School of Medicine
      Medical School - Completed 2003

    Research

    The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar, along with his colleagues from Surgery, Gastroenterology, Radiation Oncology and Radiology have formed multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine and pancreatic cancer. He is helping to develop the use of stromal agents and gene-targeted therapies in the treatment of pancreatic cancer and neuroendocrine tumors. Dr. Hendifar's research involves studying cachexia in his cancer patients. He has developed a treatment protocol in pancreatic cancer cachexia that will increase understanding of this phenomenon. The goal is to develop new therapies for this condition. One treatment, an anti-inflammatory agent, is already being investigated in colon cancer patients. Dr. Hendifar is also the primary investigator for several trials in the treatment of pancreatic cancer, colon cancer, and neuroendocrine tumors.

    PUBLICATIONS

    • Khanuja J, Gresham G, Osipov A, Tuli R, Hendifar A. Treatment and underlying mechanisms of pancreatic cancer cachexia (PANCAX study). J Clin Oncol. 2015;33.
    • Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, Li Q, Tuli R. Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma. PLoS One. 2016 Mar 25;11(3):e0152172.
    • Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS, Nikiforova MN, et al. Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2017 May;15(5):555-562. PubMed PMID: 28476735.
    • Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018 Jun 7:JCO2018785865. doi: 10.1200/JCO.2018.78.5865. [Epub ahead of print] PubMed PMID: 29878866.
    more

    Achievements

    Board Certifications

    • Board Certified in Hematology
    • Board Certified in Medical Oncology

    Awards & Activities

    • Super Doctors - 2013-present
    • Course Director, LACNETS & CFCF Annual Neuroendocrine Tumor Patient & Caregiver Educational Conference - 2015-present
    • Supportive Care Medicine Chair, Precision Promise Consortium, Pancreatic Cancer Action Network - 2016-present
    • Course Director, Gastrointestinal Cancer Conference - 2018
    more

    Patient Ratings & Comments Learn more

    Ratings

    Average Rating:
    4.9 / 5
    381 Ratings

    Rating Breakdown

    five star (355):
    four star (18):
    three star (5):
    two star (2):
    one star (1):

    Comments

    By Cedars-Sinai Patienton Jan 11, 2021

    I ound it organized

    By Cedars-Sinai Patienton Jan 04, 2021

    need more IV team access

    By Cedars-Sinai Patienton Dec 28, 2020

    They listen to your concerns

    more